Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Renewal of Skin Epidermal Stem Cells01:12

Renewal of Skin Epidermal Stem Cells

The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular cells,...
Multipotency and Niche of Bulge Stem Cell01:06

Multipotency and Niche of Bulge Stem Cell

A hair follicle or HF is a small part of the skin that produces the hair shaft. Paul Gerson Unna was the first to observe a bulge in the human hair follicle's outer root sheath (ORS). The bulge is present between the sebaceous gland and the arrector pili muscle and is the niche for hair follicle stem cells (HFSCs). The bulge is also a niche for melanocyte stem cells, and their loss results in graying of hair. The HFSCs express Sox9 and Lhx2, which help them maintain stemness and prevent...
Healing I: Introduction01:11

Healing I: Introduction

Healing is the physiological process by which the body restores the integrity and function of damaged tissues following injury. It involves a coordinated interplay of cellular proliferation, extracellular matrix remodeling, and growth factor signaling. The extent and nature of the tissue damage determine whether healing occurs by resolution, regeneration, or replacement.ResolutionResolution represents the most complete form of healing, occurring when the injury is minimal and tissue...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

The New England journal of medicine·2026
Same author

Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.

Vaccine·2022
Same author

Clinical Resolution of Red Cell Aplasia Associated del 17p Multiple Myeloma, When Treated With Bortezomib and Dexamethasone.

Journal of hematology·2020
Same author

Recent Advances in the Management of Smoldering Multiple Myeloma.

World journal of oncology·2020
Same author

The organisation, operational dynamics and structure of female sex work in Pakistan.

Sexually transmitted infections·2013
Same author

Isolated CNS relapse of CML after bone marrow transplantation.

Leukemia research·2009
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

Generation and Culturing of Primary Human Keratinocytes from Adult Skin
10:42

Generation and Culturing of Primary Human Keratinocytes from Adult Skin

Published on: December 22, 2017

Keratinocyte growth factor.

Uzma Athar1, Teresa C Gentile

  • 1SUNY Upstate Medical University, Regional Oncology Center, Division of Hematology and Oncology, Department of Medicine, Syracuse, NY 13210, USA.

Expert Opinion on Biological Therapy
|May 22, 2009
PubMed
Summary
This summary is machine-generated.

Palifermin significantly reduces the incidence and severity of mucositis, a common side effect of stem cell transplantation for hematologic malignancies. This agent improves patient functioning and reduces associated morbidity during treatment.

More Related Videos

Rapid Genetic Analysis of Epithelial-Mesenchymal Signaling During Hair Regeneration
10:09

Rapid Genetic Analysis of Epithelial-Mesenchymal Signaling During Hair Regeneration

Published on: February 28, 2013

Isolation and Culture of Primary Mouse Keratinocytes from Neonatal and Adult Mouse Skin
10:51

Isolation and Culture of Primary Mouse Keratinocytes from Neonatal and Adult Mouse Skin

Published on: July 14, 2017

Related Experiment Videos

Last Updated: Jun 23, 2026

Generation and Culturing of Primary Human Keratinocytes from Adult Skin
10:42

Generation and Culturing of Primary Human Keratinocytes from Adult Skin

Published on: December 22, 2017

Rapid Genetic Analysis of Epithelial-Mesenchymal Signaling During Hair Regeneration
10:09

Rapid Genetic Analysis of Epithelial-Mesenchymal Signaling During Hair Regeneration

Published on: February 28, 2013

Isolation and Culture of Primary Mouse Keratinocytes from Neonatal and Adult Mouse Skin
10:51

Isolation and Culture of Primary Mouse Keratinocytes from Neonatal and Adult Mouse Skin

Published on: July 14, 2017

Area of Science:

  • Oncology
  • Hematology
  • Gastroenterology

Background:

  • Mucositis affects over 90% of patients undergoing stem cell transplantation for hematologic malignancies.
  • It causes significant pain, dysphagia, decreased oral intake, and mortality.
  • Current treatments for mucositis are limited.

Purpose of the Study:

  • To review preclinical data and clinical trials of palifermin for mucositis in hematologic malignancies.
  • To include available Phase I and II data on palifermin in solid tumors.

Main Methods:

  • Review of preclinical studies on palifermin.
  • Analysis of Phase III clinical trials evaluating palifermin in hematologic malignancies.
  • Inclusion of Phase I and II data for solid tumors.

Main Results:

  • Palifermin demonstrated efficacy in decreasing the incidence, severity, and duration of mucositis in Phase III trials.
  • Palifermin has shown improvement in patient functioning during hematopoietic stem cell transplants.
  • Preclinical data supports the mechanism of action.

Conclusions:

  • Palifermin is an effective agent for managing mucositis in patients undergoing stem cell transplantation for hematologic malignancies.
  • Palifermin improves patient outcomes and reduces treatment-related morbidity.
  • Further investigation in solid tumors may be warranted.